Novel peptide conjugates for tumor-specific chemotherapy

Journal of Medicinal Chemistry

Volumn 44, Issue 9, 2001, Pages 1341-1348

  Langer, M ^a,b   Kratz, F ^c   Rothen Rutishauser, B ^b   Wunderli Allenspach, H ^b   Beck Sickinger, A G ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b ETH ZURICH   (Switzerland)

^c TUMOR BIOLOGY CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; DAUNORUBICIN; DOXORUBICIN; HYDRAZONE DERIVATIVE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; PEPTIDE; RECEPTOR SUBTYPE;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; COLORIMETRY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; INTERNALIZATION; NEUROBLASTOMA; NONHUMAN; PROTEIN EXPRESSION; TUMOR CELL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; COLORIMETRY; DAUNORUBICIN; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MICROSCOPY, CONFOCAL; NEUROPEPTIDE Y; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0035953309     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm001065f     Document Type: Article

References (59)

1. Cancer chemotherapy-principles and practice
2. Adriamycin - A review
3. Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers
4. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker
5. Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes
6. Preparation, characterization and in vitro efficacy of albumin conjugates of doxorubicin
7. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy
8. Transferrin conjugates of doxorubicin: Synthesis, characterization, cellular uptake, and in vitro efficacy
9. Acid-sensitive poly(ethylene glycol) conjugates of doxorubicin: Preparation, in vitro efficacy and intracellular distribution
10. Polymeric drug-carriers containing doxorubicin and melanocyte-stimulating hormone: In vitro and in vivo evaluation against murine melanoma
11. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy
12. Trojan peptides: The penetratin system for intracellular delivery
13. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
14. Neuropeptide Y: Complete amino acid sequence of the brain peptide
15. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors
16. Endocytosis
17. Monitoring of the internalization of neuropeptide Y on neuroblastoma cell line SK-N-MC
18. Structure-activity relationships of neuropeptide Y analogues with respect to Y1 and Y2 receptors
19. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family
20. Synthesis of new maleimide derivatives of daunorubicin and biological activity of acid labile transferrin conjugates
21. Synthesis and stability of four derivatives of the anticancer drug doxorubicin for the preparation of chemoimmunoconjugates
22. Fluorescent labeled analogues of neuropeptide Y for the characterization of cells expressing NPY receptor subtypes
23. Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells
24. A fast and inexpensive method for N-terminal fluorescein-labeling of peptides
25. Characterization of functional neuropeptide Y receptors in a human neuroblastoma cell line
26. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines
27. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP 3226
28. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226
29. Differently labeled peptide ligands for rapid investigation of receptor expression on a new human glioblastoma cell line
30. Macromolecular drug carrier systems in cancer chemotherapy: Macromolecular prodrugs
31. Macromolecule-drug conjugates in targeted cancer chemotherapy
32. Passive tumor targeting of soluble macromolecules and drug conjugates
33. Tumoritropic and lymphotropic principles of macromolecular drugs
34. Drug targeting in antineoplastic chemotherapy: Antigens and receptors in the tumor cell surface as an attack point for selective chemotherapy
35. Peptide-guided cancer drugs show promise in mice
36. A ticket to ride: Peptide radiopharmaceuticals
37. Radiolabeled peptides and other ligands for receptors overexpressed in tumor cells for imaging neoplasms
38. Neuropeptide receptors in health and disease: The molecular basis for in vivo imaging
39. Receptor targeting for tumor localisation and therapy with radiopeptides
40. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy
41. Pre-clinical experience with Re-188-RC-160, a radiolabeled somatostatin analogue for use in peptide-targeted radiotherapy
42. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent
43. Translocation of human calcitonin in respiratory nasal epithelium is associated with self-assembly in lipid membrane
44. Identification of receptor ligands with phage display peptide libraries
45. Attempts to target antitumor drugs toward opioid receptor-rich mouse tumor cells with enkephalin-ellipticinium conjugates
46. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors
47. Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis
48. Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations
49. Chemical modifications of proteins: History and applications
50. Drug-polymer conjugates containing acid-cleavable bonds
51. New hydrazone derivatives of adriamycin and their immunoconjugates - A correlation between acid stability and cytotoxicity
52. Albumin conjugates of the anticancer drug chlorambucil: Synthesis, characterization, and in vitro efficacy
53. Synthesis and in vitro efficacy of transferrin conjugates of the anticancer drug chlorambucil
54. Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing
55. Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity
56. Effect of linker variation on the stability, potency, and efficacy of carcinomareactive BR64-doxorubicin immunoconjugates
57. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates